Palvella Appoints Rare Disease Biotech Leader Matt Pauls as QTORIN Launch Approaches
PVLA•Palvella Therapeutics has appointed Matt Pauls, J.D., M.B.A., to its Board, leveraging his 25+ years leading commercial and executive roles at Savara, Soleno and Insmed. Pauls’s expertise in launch planning and commercialization will support the anticipated U.S. rollout of QTORIN™ rapamycin.
1. Board Appointment and Experience
Palvella has appointed Matt Pauls, J.D., M.B.A., to its Board of Directors. Pauls brings over 25 years of executive and board experience in rare disease biotechnology, with past leadership roles at Savara, Soleno and Insmed, where he oversaw IPOs, FDA approvals and product launches.
2. Strategic Impact on QTORIN Commercialization
Palvella anticipates leveraging Pauls’s commercialization and launch planning expertise to prepare for the potential U.S. launch of QTORIN™ rapamycin gel. His background in driving approval and market entry for therapies in areas with no approved treatments is expected to accelerate Palvella’s pipeline advancement and market positioning.
